Merus N.V.

NASDAQ:MRUS

$44.84 USD

-$0.13 (-0.29%)

Volume
267.92K
Average Volume
518.26K
Market Capitalization
$3.07B
P/E Ratio
-12.51
Dividend Yield
0.00%
Price Target
$85.00
Year High
$61.61
Year Low
$22.27
Payout Ratio
$0.00
Current Ratio
$8.32

Industry, Sector & symbol

Stock Exchange NASDAQ Global Market
CEO Dr. Sven Ante Lundberg M.D.
Industry Biotechnology
Sector Healthcare
Current Symbol MRUS
CUSIP N5749R100
CIK 0001651311
Web https://www.merus.nl
Phone 31 30 253 8800
Currency USD
Employees 172
Country NL

Liquidity

Debt-to-Equity Ratio 0.00
Payout Ratio 0.00
Current Ratio 8.32
Quick Ratio 8.32
Cash Ratio 5.41

Sales & Book Value

Annual Sales $43.95M
Price / Sales 85.44
Cash Flow -2.28
Price / Cash Flow -19.72
Price / Book 4.35

Price Target and Rating

Average Stock Price Forecast $85.00
High Stock Price Forecast $99.00
Low Stock Price Forecast $30.00
Forecast Upside/Downside -47.25%
Consensus Rating Strong Sell
Rating Score(0-5) 1
Research Coverage 10 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-3
Trailing P/E Ratio -12.51
PEG Ratio 0.35
P/E Growth 0.35
Net Income $-154.94M
Net Margin -680.61%
Pretax Margin -659.93%
Return on Equity -45.38%
Return on Assets -28.95%

Financials Score

AltmanZ Score 11.36
Piotroski Score 3.00
Working Capital 586.2M
Total Assets 844.68M
Ebit -251.41M
Market Cap 3.07B
Total Liabilities 141.42M

Poll Results

About Merus N.V. (NASDAQ:MRUS) Stock

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinic ... al trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Biotech Stock Boosted on Brand-New 'Buy' Rating

2024-11-21 10:48:35

Biotech stock Merus NV (NASDAQ:MRUS) is up 3.4% at $44.40 at last glance, though pulling back a bit from its premarket surge, after Goldman Sachs initiated coverage with a "buy" rating.

Merus to Present at Upcoming Investor Conferences

2024-11-06 16:01:00

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:

Merus: Petosemtamab Set Up For December 2024 Data Presentation

2024-11-05 13:18:14

Merus is nearing a major milestone with zenocutuzumab's potential FDA approval for NRG1+ NSCLC/PDAC, with a PDUFA date of February 4, 2025. Petosemtamab, targeting 1st and 2nd-line HNSCC, shows promise with updated data to be presented at ESMO Asia Congress in December 2024. Financially stable with $782.9 million in cash, Merus has strategic partnerships with Gilead, Eli Lilly, Incyte, and Ono Pharmaceutical, funding operations into 2028.

Merus Receives FDA extension of PDUFA for zenocutuzumab

2024-11-05 06:30:00

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the United States Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for zenocutuzumab (Zeno) Biologics License Application (BLA) currently under priority review.

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates

2024-10-31 10:26:14

Merus N.V. (MRUS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.43 per share a year ago.

Frequently Asked Questions

What is the current Merus N.V. (MRUS) stock price?

Merus N.V.(NASDAQ:MRUS) stock price is $44.84 in the last trading session. During the trading session, MRUS stock reached the peak price of $61.61 while $22.27 was the lowest point it dropped to. The percentage change in MRUS stock occurred in the recent session was --0.29% while the dollar amount for the price change in MRUS stock was -$-0.13.

MRUS's industry and sector of operation?

The NASDAQ listed MRUS is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of MRUS?

Dr. Sven Ante Lundberg M.D. | Chief Executive Officer, President & Executive Director
Mr. Peter B. Silverman J.D. | EVice President, Company Secretary, Chief Operating Officer, General Counsel, Chief Intellectual Property Officer & Head of US Legal
Dr. Hennie Hoogenboom | Co-Founder and Scientific Advisor
Ms. Kathleen Farren | IR & Corporate Communications Officer
Ms. Audrey Bergan | Chief People Officer

How many employees does MRUS have?

Number of MRUS employees currently stands at 172. MRUS operates from Yalelaan 62, Utrecht, None 3584 CM, NL.

Link for MRUS official website?

Official Website of MRUS is: https://www.merus.nl

How do I contact MRUS?

MRUS could be contacted at phone #31 30 253 8800 and can also be accessed through its website. MRUS operates from Yalelaan 62, Utrecht, None 3584 CM, NL.

How many shares of MRUS are traded daily?

The average number of MRUS shares traded daily for last 3 months was 518.26K.

What is the market cap of MRUS currently?

The market value of MRUS currently stands at $3.07B with its latest stock price at $44.84